Abstract
Endothelin-1 (ET-1) is a potent vasoconstrictor peptide apparently involved in a number of vascular diseases in man. Nonetheless, its determination in biological samples is difficult, and data on plasma or urine concentrations are controversial. We investigated different sample preparation procedures as well as different radioimmunoassays for their influence on ET-1 measurement. Recovery of ET-1 depended on the extraction procedure, the type and size of the extraction columns and on the biological matrix itself. Incomplete removal of matrix components by the extraction leads to the formation of particulate matter in the evaporated eluate. When dissolved in assay buffer, ET-1 was found to be absorbed to and only partly released from these particulates, so that it was not accessible for measurement in a radioimmunoassay. This was the case for all extraction procedures investigated except for that involving acetic acid. HPLC analysis of spiked samples revealed that ET-1 is in part degraded during extraction, most probably to Meth-sulphoxide ET-1. Dilution curves of synthetic pure ET-1 standards from different suppliers, prepared either in plasma with subsequent extraction or in assay buffer of the respective radioimmunoassay, resulted in considerable differences in the measured values for ET-1-immunoreactivity. Every radioimmunoassay tested had a specific pattern of recognizing different synthetic ET-1 standards. In conclusion, the measurement of ET-1-immunoreactivity is strongly influenced by the experimental conditions of sample preparation as well as by the radioimmunoassay employed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- ET-1:
-
Endothelin-1
- AA:
-
acetic acid
- TFA:
-
trifluoroacetic acid
- MeOH:
-
methanol
- EtOH:
-
ethanol
- RIA:
-
radioimmunoassay
- HPLC:
-
high-pressure liquid chromatography
References
Yanagisawa M, Kurihara H, Kimura S et al (1988) A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332:411–415
Salminen K, Tikkanen I, Saijonmaa O, Nieminen M, Fyhrquist F, Frick MH (1989) Modulation of coronary tone in acute myocardial infarction by endothelin. Lancet II:747
Toyo-oka T, Aizawa T, Suzuki N et al (1991) Increased plasma level of endothelin-1 and coronary spasm induction in patients with vasospastic angina pectoris. Circulation 83:476–483
Stewart DJ, Levy RD, Cernacek P, Langleben D (1991) Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease. Ann Intern Med 114:464–469
Lerman A, Click RL, Narr BJ et al (1991) Elevation of plasma endothelin associated with systemic hypertension in humans following orthotopic liver transplantation. Transplantation 51:646–650
Ehrenreich H, Anderson RW, Fox CH et al (1990) Endothelins, peptides with potent vasoactive properties, are produced by human macrophages. J Exp Med 172:1741–1748
Masaoka H, Suzuki R, Hirata Y, Emori T, Marumo F, Hirakawa K (1989) Raised plasma endothelin in aneurysmal subarachnoid haemorrhage. Lancet II:1402
Ehrenreich H, Lange M, Near KA et al (1992) Longterm monitoring of immunoreactive endothelin-1 and endothelin-3 in ventricular cerebrospinal fluid, plasma, and 24-h urine of patients with subarachnoid hemorrhage. Res Exp Med 192:257–268
Collier A, Leach JP, McLellan A, Jardine A, Morton JJ, Smal M (1992) Plasma endothelinlike immunoreactivity level sin IDDM patients with microalbuminuria. Diabetes Care 15:1038–40
Kawamura M, Ohgarawa H, Naruse M et al (1992) Increased plasma endothelin in NIDDM patients with retinopathy. Diabetes Care 15:1096–97
Goebel F-D, Rolinski B, Rieckmann P, et al (1992) Involvement of endothelins, peptides with potent vasoactive properties in HIV-1 encephalopathy. In: Weis, S, Hippius H (eds) HIV-1 infection of the central nervous system. Hogrefe & Huber, Berne, pp 147–157
Rolinski B, Geier SA, Sadri I, et al (in press) Endothelin-1 Immunoreactivity in plasma is elevated in HIV-1 infected patients with retinal microangiopathic syndrome. Clin Invest
Kanno K, Hirata Y, Shirichi M, Marumo F (1991) Plasma endothelin-1 levels in patients with diabetes mellitus with or without vascular complication. J Cardiovasc Pharmacol 17 [Suppl 7]:475–476
Totsune K, Sone M, Takahashi K et al (1991) Immunoreactive endothelin in urine of patients with or without diabetes mellitus. J Cardiovasc Pharmacol 17 [Suppl 7]:423–424
Zamora MR, O'Brien RF, Rutherford RB, Weil JV (1990) Serum endothelin-1 concentrations and cold provocation in primary Raynaud's phenomenon. Lancet 336:1144–1147
Von Bierbrauer A, Herzog U, Ehlenz K, Wichert P (1991) Serum endothelin in patients with Raynaud's syndrome before and following cold provocation. Vasa [Suppl 33]:156–157
Bradford MM (1976) A rapid and sensitive method for the quantitation of protein utilizing the principle of protein-dye binding. Annal Biochem 72:248–254
Tompkins S, Glenn J, Greene PK, et al (1993) Analysis of endothelin in serum and urine from patients with various pathological conditions (abstract). Third International Conference on Endothelin, Houston 1993
Florijn LW, Derkx FHM, Visser W et al (1991) Plasma immunoreactive endothelin-1 in pregnant women with and without pre-eclampsia. J Cardiovasc. Pharmacol 17 [Suppl 7]:446–448
Hartter E, Schiessler R, Petzl DH, Schuller W, Kargl R, Woloszczuk W (1990) Radioimmunoassay and plasma levels of endothelin, a vasoconstrictor of potential importance in renal disease. Contrib Nephrol 83:31–38
Jori G, Rossi E, Rubaltelli FF (1980) Phototherapy-induced covalent binding of bilirubin to serum albumin. Pediatr Res 14:1363–1366
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rolinski, B., Sadri, I., Bogner, J. et al. Determination of endothelin-1 immunoreactivity in plasma, cerebrospinal fluid and urine. Res. Exp. Med. 194, 9–24 (1994). https://doi.org/10.1007/BF02576362
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02576362